Scarica l'app Stockscreener
61.18
1.24%
0.75
Pre-mercato:
61.24
0.06
+0.10%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DXCM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$60.43
Aprire:
$61.09
Volume 24 ore:
11.62M
Relative Volume:
2.07
Capitalizzazione di mercato:
$23.99B
Reddito:
$4.30B
Utile/perdita netta:
$571.50M
Rapporto P/E:
42.83
EPS:
1.4285
Flusso di cassa netto:
$570.80M
1 W Prestazione:
-11.63%
1M Prestazione:
-8.75%
6M Prestazione:
-25.04%
1 anno Prestazione:
-12.22%
Intervallo 1D:
$58.88
$62.39
Intervallo di 1 settimana:
$56.45
$69.17
Portata 52W:
$56.45
$93.25
Dexcom Inc Stock (DXCM) Company Profile
Nome
Dexcom Inc
Settore
Industria
Telefono
(858) 200-0200
Indirizzo
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Confronta DXCM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
61.18 | 23.57B | 4.30B | 571.50M | 570.80M | 1.4285 |
|
ABT
Abbott Laboratories
|
125.80 | 215.34B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.84 | 146.15B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
SYK
Stryker Corp
|
362.61 | 136.97B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
90.42 | 115.69B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
84.15 | 48.77B | 5.88B | 1.34B | 577.90M | 2.3455 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-21 | Ripresa | Stifel | Buy |
| 2025-09-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Iniziato | Argus | Buy |
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-02-03 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Iniziato | Redburn Atlantic | Neutral |
| 2024-03-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2023-01-26 | Iniziato | Wolfe Research | Outperform |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-15 | Iniziato | Bernstein | Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-28 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2021-01-06 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-02 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Reiterato | Piper Sandler | Overweight |
| 2020-05-14 | Iniziato | Wells Fargo | Equal Weight |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-11-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-10-23 | Iniziato | Stifel | Buy |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-19 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-09-12 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Reiterato | Canaccord Genuity | Buy |
| 2018-07-02 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
| 2018-05-03 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-04 | Iniziato | Goldman | Sell |
| 2018-04-04 | Iniziato | Guggenheim | Neutral |
| 2018-03-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Reiterato | Wedbush | Outperform |
Mostra tutto
Dexcom Inc Borsa (DXCM) Ultime notizie
Is DexCom Inc. (DC4) stock supported by free cash flow2025 Volume Leaders & Advanced Swing Trade Entry Alerts - newser.com
Will breakout in DexCom Inc. lead to full recoveryTrade Volume Summary & Weekly High Return Forecasts - newser.com
Join Class Action to Recover Losses from DexCom, Inc. (DXCM)Contact Levi & Korsinsky Before December 26, 2025 - ACCESS Newswire
Stockholder Alert: Robbins LLP Informs Investors of the Dexcom, Inc. Class Action Lawsuit - Your Wyoming Link
Levi & Korsinsky Moves to SueWallSt for DexCom, Inc. Investors That Lost Money - ACCESS Newswire
DXCM LAWSUIT ALERT: Levi & Korsinsky Notifies DexCom, Inc. InvestorsLead Plaintiff Deadline December 26, 2025 - ACCESS Newswire
DexCom (NASDAQ:DXCM) Price Target Lowered to $95.00 at UBS Group - MarketBeat
Securities Fraud Class Action Filed Against DexCom, Inc. (DXCM)Levi & Korsinsky Reminds Investors of December 26, 2025 - ACCESS Newswire
DXCM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that DexCom, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
ROSEN, A LEADING LAW FIRM, Encourages DexCom, Inc. Investors to Secure Counsel Before Important ... - Bluefield Daily Telegraph
ROSEN, A LEADING LAW FIRM, Encourages DexCom, Inc. - GlobeNewswire
DXCM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Dexcom recalls G6 CGM app over software problem - MedTech Dive
DexCom (NASDAQ:DXCM) Given "Buy" Rating at Truist Financial - MarketBeat
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Is DexCom Inc. (DC4) stock cheap by valuation metricsMarket Risk Summary & Community Consensus Picks - newser.com
Can DexCom Inc. (DC4) stock hit consensus price targetsPortfolio Growth Summary & Weekly Top Gainers Alerts - newser.com
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit - MarketScreener
Freestone Capital Holdings LLC Purchases 7,242 Shares of DexCom, Inc. $DXCM - MarketBeat
What MACD and RSI say about DexCom Inc.CEO Change & Smart Money Movement Alerts - newser.com
DexCom, Inc. Hits New 52-Week Low at $56.45 Amid Market Struggles - Markets Mojo
Has DexCom Inc. found a price floor2025 Big Picture & Real-Time Volume Surge Alerts - newser.com
Will DexCom Inc. stock continue dividend increasesDollar Strength & Verified Chart Pattern Trade Signals - newser.com
Building trade automation scripts for DexCom Inc.July 2025 Breakouts & Weekly Setup with High ROI Potential - newser.com
DexCom, Inc. Experiences Valuation Adjustment Amidst Competitive Market Dynamics - Markets Mojo
Can technical indicators confirm DexCom Inc.’s reversalEarnings Recap Summary & Proven Capital Preservation Methods - newser.com
DexCom, Inc. (NASDAQ:DXCM) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Securities Class Action Lawsuit Filed Against DexCom, Inc. (DXCM)Levi & Korsinsky Represents Shareholders - ACCESS Newswire
Is DexCom Inc. (DC4) stock a buy for dividend portfoliosPrice Action & Safe Investment Capital Preservation Plans - newser.com
Lost Money on DexCom, Inc. (DXCM)? Urged to Join Class Action Before December 26, 2025Contact Levi & Korsinsky - ACCESS Newswire
DexCom (DXCM): UBS Lowers Price Target to $95, Maintains 'Buy' R - GuruFocus
DexCom Faces Class Action Over Alleged Investor Deception - TipRanks
DXCM CLASS ACTION LAWSUIT: A Securities Fraud Class Action - GlobeNewswire
DexCom Stock Rises 3.7% on November 3, 2025 | DXCM NewsNews and Statistics - IndexBox
DexCom (DXCM) Stock Is Up, What You Need To Know - TradingView
DexCom Growth Outlook Likely Sustainable, UBS Says - MarketScreener
UBS Adjusts DexCom Price Target to $95 From $106, Maintains Buy Rating - MarketScreener
Truist Securities Reiterates Buy Rating on DexCom (DXCM) Despite - GuruFocus
DXCM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Is DexCom Inc. (DC4) stock a top pick for value investorsPortfolio Value Summary & Verified Swing Trading Watchlist - newser.com
Can DexCom Inc. stock maintain operating marginsInsider Selling & Stock Portfolio Risk Management - newser.com
Statistical indicators supporting DexCom Inc.’s strengthM&A Rumor & Safe Entry Zone Identification - newser.com
AlphaQuest LLC Sells 4,660 Shares of DexCom, Inc. $DXCM - Defense World
Will DexCom Inc. stock maintain momentum in 2025Inflation Watch & Weekly Momentum Stock Picks - newser.com
What does recent volatility data suggest for DexCom Inc.2025 Big Picture & Verified Entry Point Signals - newser.com
Is DexCom Inc. stock reversal real or fakeQuarterly Investment Review & Daily Stock Trend Reports - newser.com
FY2025 EPS Estimates for DexCom Increased by Leerink Partnrs - MarketBeat
What is William Blair's Forecast for DexCom FY2025 Earnings? - MarketBeat
Is DexCom Inc. stock attractive for passive investors2025 Momentum Check & Safe Capital Preservation Plans - newser.com
DexCom Inc. stock chart pattern explainedMarket Performance Summary & Consistent Profit Focused Trading Strategies - newser.com
Can DexCom Inc. stock sustain free cash flow growthEarnings Trend Report & Advanced Swing Trade Entry Alerts - newser.com
Dexcom Inc Azioni (DXCM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.91%
0.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):